Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction

Silvain, Johanne; Kernéis, Mathieu; Zeitouni, Michel; Lattuca, Benoît; Galier, Sophie; Brugier, Delphine; Mertens, E.; Procopi, Niki; Suc, Gaspard; Salloum, Tomy; Frisdal, Éric; Goff, Wilfried Le; Collet, Jean‐Philippe; Vicaut, Éric; Lesnik, Philippe; Montalescot, Gilles; Guérin, Maryse

doi:10.1016/j.jacc.2020.08.026

Cited by 26 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further experiments showed that THP significantly reduced cardiomyocyte apoptosis after OGD exposure, as indicated by the recovery of cell viability (Figure 7), the decreased ratio of cleaved caspase-3 protein expression to caspase-3 protein expression, and reduced mRNA levels of Bax, Bcl-2 and p53 (Figure 8). IL-6, IL-1β, and TNFα are crucial cytokines in the inflammatory response and immune reaction of MI patients (Di Stefano et al, 2009;Silvain et al, 2020). Therefore, we investigated the expression of IL-6, IL-1β, and TNFα using RT-qPCR analysis and found that their expression was significantly augmented by the OGD stimulus and observably diminished by THP treatment in a dose-dependent manner (Figure 8).…”

Section: Discussionmentioning

confidence: 99%

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification

Huang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Myocardial infarction (MI), characterized by reduced blood flow to the heart, is a coronary artery disorder with the highest morbidity and mortality among cardiovascular diseases. Consequently, there is an urgent need to identify effective drugs to treat MI. Rhizoma Corydalis (RC) is the dry tuber of Corydalis yanhusuo W.T. Wang, and is extensively applied in treating MI clinically in China. Its underlying pharmacological mechanism remains unknown. This study aims to clarify the molecular mechanism of RC on MI by utilizing network pharmacology and experimental verification.Methods: Based on network pharmacology, the potential targets of the RC ingredients and MI-related targets were collected from the databases. Furthermore, core targets of RC on MI were identified by the protein-protein interaction (PPI) network and analyzed with Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Molecular docking was used to validate the binding affinity between the core targets and the bioactive components. Oxygen-glucose deprivation (OGD) was performed on H9c2 cells to mimic MI in vitro. A Cell Counting Kit-8 assay was used to assess the cardioprotective effect of the active ingredient against OGD. Western blot analysis and RT-qPCR were used to measure the cell apoptosis and inflammation level of H9c2 cells.Results: The network pharmacology obtained 60 bioactive components of RC, 431 potential targets, and 1131 MI-related targets. In total, 126 core targets were screened according to topological analysis. KEGG results showed that RC was closely related to the phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB, also called Akt) signaling pathway. The experimental validation data showed that tetrahydropalmatine (THP) pretreatment preserved cell viability after OGD exposure. THP suppressed cardiomyocyte apoptosis and inflammation induced by OGD, while LY294002 blocked the inhibition effect of THP on OGD-induced H9c2 cell injury. Moreover, the molecular docking results indicated that THP had the strongest binding affinity with Akt over berberine, coptisine, palmatine, and quercetin.Conclusion: THP, the active ingredient of RC, can suppress OGD-induced H9c2 cell injury by activating the PI3K/Akt pathway, which in turn provides a scientific basis for a novel strategy for MI therapy and RC application.

show abstract

Section: Discussionmentioning

confidence: 99%

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification

Huang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In patients after treatment with colchicine (n = 446), the mean value of hs-CRP was 1.78 mg% compared with 3.7 mg% in the placebo group (n = 416) (Figure 3D). In patients with ACS, elevated levels of hs -CRP, interleukin-1, and interleukin-6 are indicators of the risk of cardiovascular complications (28)(29)(30)(31). Treatment with colchicine in comparison with placebo leads to a greater reduction in the volume of atherosclerotic plaque, and changes in its volume also correlate with changes in serum hs-CRP levels (8).…”

Section: Discussionmentioning

confidence: 99%

A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease

Grajek

Michalak

Urbanowicz

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Evidence from recent studies has shown the benefits of colchicine for patients with coronary artery disease. The aim was to assess the effect of colchicine treatment on cardiovascular events, with an estimation of the risk of discontinuation and net clinical benefit.Methods and Results: Fourteen trials with a total of 13,186 patients were selected through a systematic search. Colchicine therapy significantly reduced the relative risk of primary endpoint by about 30% [RR 0.70 (95%CI:0.56–0.88)]. Compared with placebo, colchicine significantly reduced the risk of ischemia-driven revascularization [RR 0.57 (95%CI 0.41–0.80)], ischemia-driven revascularization and resuscitation [RR 0.50 (95%CI 0.34–0.73)], myocardial infarction [RR 0.73 (95%CI 0.57–0.95)], and stroke [RR 0.49 (95%CI 0.30–0.7)]. Patients treated with colchicine in comparison with placebo have a significant increase in the risk of treatment cessation (RR 1.60 95%CI 1.06–2.42). However, in the analysis which excluded studies without placebo, the relative risk of discontinuation was smaller (RR 1.34 95%CI 0.97–1.84) and in the three largest studies, the risk of discontinuation was lower and insignificant [RR 1.26 (95%CI 0.87–1.83)]. The net clinical benefit was 17.8/1,000 patients (p < 0.001).Conclusion: In coronary artery disease, low-dose colchicine significantly reduces the risk of the primary composite endpoint by about 30%. The drug should be considered as part of the preventive treatment in patients with good tolerance.

show abstract

“…Patients of the e-Paris registry free of prior cardiovascular disease admitted for a first ST-segment elevation myocardial infarction (STEMI) between January 2000 and October 2018 were stratified into three age categories: premature STEMI for patients aged <55 years old, average age category between 55 and 65 years old and older age category >65 years old 8 12. As previously described,13 14 the e-PARIS registry is a prospective cohort of patients admitted with STEMI at the University Hospital of Pitié-Salpêtrière, Paris, France. A prespecified set of baseline clinical, biological and angiographic characteristics were collected at patient’s admission, along with the follow-up of major adverse cardiovascular events and mortality.…”

Section: Methodsmentioning

confidence: 99%

Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines

Zeitouni

Sulman

Silvain

et al. 2022

Heart

Self Cite

View full text Add to dashboard Cite

ObjectiveTo determine if the changes in the European Society Cardiology/European Atherosclerotic Society (ESC/EAS) guidelines improved the identification for primary prevention therapy in young adults at risk of a premature myocardial infarction.MethodsPatients admitted for a first ST-segment elevation myocardial infarction (STEMI) in the ePARIS registry (n=2757) between 2010 and 2018 were classified by age: <55, 55–65 and >65 years old. Using Systematic Coronary Risk Estimation 2, we evaluated whether patients would have been detected and treated with primary prevention statins before their first STEMI based on the 2021 EAS/ESC guidelines versus 2019 and 2016 guidelines. Eligibility for intensive proprotein convertase subtilisin/kexin type 9 (PCSK9i) in secondary prevention was also assessed.ResultsFollowing 2021 ESC guidelines, 62.5% of individuals aged <55 years old would have been eligible for statins before their first STEMI, similarly to older age categories. In comparison, only 17% and 18% of young individuals would have been eligible for primary prevention statins prior to their first STEMI with 2016 and 2019 guidelines, compared with group 55–65 years (41% and 35%) and >65 years old (19% and 72%), p<0.01. After their first STEMI, 25% of patients <55 years would be eligible for PCSK9i, compared with 23.2% and 15% in patients aged 55–65 years and >65 years.ConclusionsThe 2021 ESC guidelines allowed a much better detection of young individuals before their first STEMI than prior ESC guidelines. In secondary prevention, most of young individuals did not reach low-density lipoprotein cholesterol levels recommended, but only one quarter would be eligible for PCSK9i.

show abstract

Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction

Cited by 26 publications

References 25 publications

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification

A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease

Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines

Contact Info

Product

Resources

About